Marta C Nunes1, Clare L Cutland1, Stephanie Jones1, Andrea Hugo1, Richard Madimabe1, Eric A F Simões2, Adriana Weinberg3, Shabir A Madhi4. 1. Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa2Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa. 2. Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa3Department of Pediatrics, University of Colorado and Center for Global Health, Aurora. 3. Departments of Pediatrics, Medicine, and Pathology, University of Colorado, Aurora. 4. Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa2Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa5National Institute for Communicable Diseases, Division of National Health Laboratory Service, Centre for Vaccines and Immunology, Johannesburg, South Africa.
Abstract
IMPORTANCE: Influenza immunization of women during pregnancy protects the young infants against influenza illness. The duration of this protection remains unclear. OBJECTIVE: To evaluate the duration of infant protection conferred by maternal immunization and its association with transplacental antibody transfer. DESIGN, SETTING, AND PARTICIPANTS: Infants born to women who participated in a randomized, double-blind, placebo-controlled clinical trial in 2011 and 2012 on the safety, immunogenicity, and efficacy of trivalent inactivated influenza vaccine (IIV3) during pregnancy were followed up during the first 6 months of life for polymerase chain reaction (PCR)-confirmed influenza illness. In a secondary analysis of a subset of infants, hemagglutination inhibition (HAI) antibodies were measured. The study was performed at a single center in South Africa. The secondary analysis was performed in October 2014. EXPOSURE: Maternal immunization for influenza. MAIN OUTCOMES AND MEASURES: The vaccine's efficacy against PCR-confirmed influenza illness and the percentage of infants with HAI titers of 1:40 or more by age group. RESULTS: There were 1026 infants (47.2% female) born to IIV3 recipients and 1023 infants (47.3% female) born to placebo recipients who were included in the analysis of the vaccine's efficacy. The vaccine's efficacy against PCR-confirmed influenza illness was highest among infants 8 weeks of age or younger at 85.6% (95% CI, 38.3%-98.4%) and decreased with increasing age to 25.5% (95% CI, -67.9% to 67.8%) among infants 8 to 16 weeks of age and to 30.3% (95% CI, -154.9% to 82.6%) among infants 16 to 24 weeks of age. Similarly, in the IIV3 group, the percentage of infants with HAI titers of 1:40 or more to the influenza vaccine strains decreased from more than 56% in the first week of life to less than 40% at 16 weeks of age and less than 10.0% at 24 weeks of age. CONCLUSIONS AND RELEVANCE: Maternal immunization conferred protection against infection in the infants for a limited period during early life. The lack of protection beyond 8 weeks of age correlated with a decrease in maternally derived antibodies. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01306669.
RCT Entities:
IMPORTANCE: Influenza immunization of women during pregnancy protects the young infants against influenza illness. The duration of this protection remains unclear. OBJECTIVE: To evaluate the duration of infant protection conferred by maternal immunization and its association with transplacental antibody transfer. DESIGN, SETTING, AND PARTICIPANTS: Infants born to women who participated in a randomized, double-blind, placebo-controlled clinical trial in 2011 and 2012 on the safety, immunogenicity, and efficacy of trivalent inactivated influenza vaccine (IIV3) during pregnancy were followed up during the first 6 months of life for polymerase chain reaction (PCR)-confirmed influenza illness. In a secondary analysis of a subset of infants, hemagglutination inhibition (HAI) antibodies were measured. The study was performed at a single center in South Africa. The secondary analysis was performed in October 2014. EXPOSURE: Maternal immunization for influenza. MAIN OUTCOMES AND MEASURES: The vaccine's efficacy against PCR-confirmed influenza illness and the percentage of infants with HAI titers of 1:40 or more by age group. RESULTS: There were 1026 infants (47.2% female) born to IIV3 recipients and 1023 infants (47.3% female) born to placebo recipients who were included in the analysis of the vaccine's efficacy. The vaccine's efficacy against PCR-confirmed influenza illness was highest among infants 8 weeks of age or younger at 85.6% (95% CI, 38.3%-98.4%) and decreased with increasing age to 25.5% (95% CI, -67.9% to 67.8%) among infants 8 to 16 weeks of age and to 30.3% (95% CI, -154.9% to 82.6%) among infants 16 to 24 weeks of age. Similarly, in the IIV3 group, the percentage of infants with HAI titers of 1:40 or more to the influenza vaccine strains decreased from more than 56% in the first week of life to less than 40% at 16 weeks of age and less than 10.0% at 24 weeks of age. CONCLUSIONS AND RELEVANCE: Maternal immunization conferred protection against infection in the infants for a limited period during early life. The lack of protection beyond 8 weeks of age correlated with a decrease in maternally derived antibodies. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01306669.
Authors: Ousseny Zerbo; G Thomas Ray; Lea Zhang; Kristin Goddard; Bruce Fireman; Alyce Adams; Saad Omer; Martin Kulldorff; Nicola P Klein Journal: Am J Epidemiol Date: 2020-11-02 Impact factor: 4.897
Authors: Beth C Holbrook; Ralph B D'Agostino; S Tyler Aycock; Matthew J Jorgensen; Mallinath B Hadimani; S Bruce King; Martha A Alexander-Miller Journal: Vaccine Date: 2017-09-28 Impact factor: 3.641
Authors: Yvette N Löwensteyn; Harish Nair; Marta C Nunes; Ichelle van Roessel; Femke S Vernooij; Joukje Willemsen; Louis J Bont; Natalie I Mazur Journal: EClinicalMedicine Date: 2021-06-10
Authors: Reagan M Mogire; John Muthii Muriuki; Alireza Morovat; Alexander J Mentzer; Emily L Webb; Wandia Kimita; Francis M Ndungu; Alex W Macharia; Clare L Cutland; Sodiomon B Sirima; Amidou Diarra; Alfred B Tiono; Swaib A Lule; Shabir A Madhi; Andrew M Prentice; Philip Bejon; John M Pettifor; Alison M Elliott; Adebowale Adeyemo; Thomas N Williams; Sarah H Atkinson Journal: Nutrients Date: 2022-03-25 Impact factor: 5.717